OxiWear has developed an ear-wearable that continuously measures blood oxygen at medical-grade accuracy, issues haptic alerts as levels fall, and can send emergency texts with location to contacts. The device targets chronic disease patients prone to hypoxia (pulmonary hypertension, COPD, cystic fibrosis, pulmonary fibrosis, long-COVID and others) and high-altitude or high-performance athletes; the company also sees use cases in military and first-responder settings. OxiWear says current market devices provide only spot or sleep readings, whereas its product aims to deliver continuous readings while users are active. The founder designed the first prototype from personal need after repeated hypoxic events and cardiac arrests. The company holds trademarks and patents in the U.S. and Southeast Asia, is conducting beta testing for a consumer release in July 2022, and is working toward FDA approvals and hospital research partnerships.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2022